The invention discloses an avermectin B1a high-yielding strain, which is classified and named streptomyces avermitilis AVE 07-N2-16515, and is preserved in a China type culture preservation centre (CCTCC) with the preservation number of CCTCC NO: M2012094. The avermectin B1a high-yielding strain disclosed by the invention is obtained by combining low-energy nitrogen ion implantation-lithium chloride (N<+>-LiCl) compound mutation with ultraviolet ray-lithium chloride (UV-LiCl) compound mutation, primarily screening, and performing shake-flask fermentation secondary screening, and is used as a starting strain for next mutation, so that the target strain AVE07-N2-16515 is finally screened. The obtained strain can greatly increase the avermectin B1a component and reduce other components in fermentation products, and is good in hereditary stability. The strain is fermented in a 5L fermentation tank to produce avermectin B1a by utilizing glucose as a quick-acting carbon source and cornstarch as a delayed-action carbon source, the titer can achieve 3048 mu g / m, which is improved by 23.4% as compared with the original starting strain AVE07; and the strain can be applied on industrial production, greatly improves a fermenting unit, and has great economic application value.